- Home
- PLUR vs PRLD Comparison
PLUR vs PRLD Comparison
Compare PLUR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- PRLD
- Stock Information
- Founded
- PLUR 2001
- PRLD 2016
- Country
- PLUR Israel
- PRLD United States
- Employees
- PLUR N/A
- PRLD N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- PLUR Health Care
- PRLD Health Care
- Exchange
- PLUR Nasdaq
- PRLD Nasdaq
- Market Cap
- PLUR 41.9M
- PRLD 48.6M
- IPO Year
- PLUR N/A
- PRLD 2020
- Fundamental
- Price
- PLUR $5.88
- PRLD $0.78
- Analyst Decision
- PLUR Strong Buy
- PRLD Strong Buy
- Analyst Count
- PLUR 1
- PRLD 2
- Target Price
- PLUR $12.00
- PRLD $4.50
- AVG Volume (30 Days)
- PLUR 62.9K
- PRLD 221.0K
- Earning Date
- PLUR 05-13-2025
- PRLD 08-11-2025
- Dividend Yield
- PLUR N/A
- PRLD N/A
- EPS Growth
- PLUR N/A
- PRLD N/A
- EPS
- PLUR N/A
- PRLD N/A
- Revenue
- PLUR $1,034,000.00
- PRLD $7,000,000.00
- Revenue This Year
- PLUR $472.39
- PRLD N/A
- Revenue Next Year
- PLUR $254.29
- PRLD N/A
- P/E Ratio
- PLUR N/A
- PRLD N/A
- Revenue Growth
- PLUR 203.23
- PRLD N/A
- 52 Week Low
- PLUR $3.33
- PRLD $0.61
- 52 Week High
- PLUR $7.13
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- PLUR 66.26
- PRLD 42.16
- Support Level
- PLUR $4.61
- PRLD $0.77
- Resistance Level
- PLUR $5.40
- PRLD $0.84
- Average True Range (ATR)
- PLUR 0.55
- PRLD 0.07
- MACD
- PLUR 0.13
- PRLD -0.02
- Stochastic Oscillator
- PLUR 91.46
- PRLD 16.04
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.